Kumi Shidara

740 citations

30 papers · 586 indexed · h-index 16

Rheumatology top 2%
- Rheumatoid Arthritis Research and Therapies 28
- Systemic Lupus Erythematosus Research 7
Hematology top 10%
- Autoimmune and Inflammatory Disorders Research 8
Genetics top 10%
- Chronic Lymphocytic Leukemia Research 8
Pathology and Forensic Medicine
- Lymphoma Diagnosis and Treatment 9
Immunology
- Biosimilars and Bioanalytical Methods 5
Pulmonary and Respiratory Medicine
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 5
Hepatology
- Hepatitis C virus research 5

Co-authors: Hisashi Yamanaka Shigeki Momohara Ayako Nakajima Eisuke Inoue Atsuo Taniguchi Daisuke Hoshi Eiichi Tanaka Yohei Seto
Cited by: Rheumatology Hematology Genetics
Partner nations: Japan Czechia

In The Last Decade

Kumi Shidara

30 papers receiving 567 citations

Peers

Countries citing papers authored by Kumi Shidara

Since Specialization

Citations

This map shows the geographic impact of Kumi Shidara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kumi Shidara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kumi Shidara more than expected).

Fields of papers citing papers by Kumi Shidara

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kumi Shidara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kumi Shidara. The network helps show where Kumi Shidara may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Kumi Shidara, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kumi Shidara Line = papers co-authored together Kumi Shidara links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort Yoko Shimizu,Ayako Nakajima,Eisuke Inoue,Kumi Shidara,Naoki Sugimoto,Yohei Seto,Eiichi Tanaka,Shigeki Momohara,Atsuo Taniguchi,Hisashi Yamanaka	2017	24
2	Incidence of comprehensive hospitalization due to infection, cardiovascular disease, fractures, and malignancies in patients with rheumatoid arthritis Naoki Sugimoto,Ayako Nakajima,Eisuke Inoue,Kumi Shidara,Hiroyuki Yamashita,Akio Mimori,Hitoshi Tokuda,Yohei Seto,Eiichi Tanaka,Shigeki Momohara,Atsuo Taniguchi,Hisashi Yamanaka	2017	9
3	Continual Maintenance of Remission Defined by the ACR/EULAR Criteria in Daily Practice Leads to Better Functional Outcomes in Patients with Rheumatoid Arthritis Kumi Shidara,Ayako Nakajima,Eisuke Inoue,Daisuke Hoshi,Naoki Sugimoto,Yohei Seto,Eiichi Tanaka,Shigeki Momohara,Atsuo Taniguchi,Hisashi Yamanaka	2016	8
4	Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012 Eri Sato,Eiichi Tanaka,Moeko Ochiai,Yoko Shimizu,Akiko Kobayashi,Kumi Shidara,Daisuke Hoshi,Naoki Sugimoto,Eisuke Inoue,Yohei Seto,Ayako Nakajima,Atsuo Taniguchi,Shigeki Momohara,Hisashi Yamanaka	2015	10
5	Profiles of EQ-5D utility scores in the daily practice of Japanese patients with rheumatoid arthritis; Analysis of the IORRA database Daisuke Hoshi,Eiichi Tanaka,Ataru Igarashi,Eisuke Inoue,Akiko Kobayashi,Naoki Sugimoto,Kumi Shidara,Eri Sato,Yohei Seto,Ayako Nakajima,Shigeki Momohara,Atsuo Taniguchi,Kiichiro Tsutani,Hisashi Yamanaka	2015	24
6	Presence of comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with rheumatoid arthritis Ayako Nakajima,Eisuke Inoue,Yoko Shimizu,Akiko Kobayashi,Kumi Shidara,Naoki Sugimoto,Yohei Seto,Eiichi Tanaka,Atsuo Taniguchi,Shigeki Momohara,Hisashi Yamanaka	2014	41
7	Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study Eiichi Tanaka,Eisuke Inoue,Daisuke Hoshi,Yoko Shimizu,Akiko Kobayashi,Naoki Sugimoto,Kumi Shidara,Eri Sato,Yohei Seto,Ayako Nakajima,Shigeki Momohara,Atsuo Taniguchi,Hisashi Yamanaka	2014	17
8	Functional disability can deteriorate despite suppression of disease activity in patients with rheumatoid arthritis: a large observational cohort study Yohei Seto,Eisuke Inoue,Kumi Shidara,Daisuke Hoshi,Naoki Sugimoto,Eri Sato,Eiichi Tanaka,Ayako Nakajima,Atsuo Taniguchi,Shigeki Momohara,Hisashi Yamanaka	2013	11
9	Disability is the major negative predictor for achievement of Boolean-based remission in patients with rheumatoid arthritis treated with tocilizumab Daisuke Hoshi,Ayako Nakajima,Kumi Shidara,Yohei Seto,Eiichi Tanaka,Atsuo Taniguchi,Shigeki Momohara,Hisashi Yamanaka	2013	9
10	The Influence of Individual Joint Impairment on Functional Disability in Rheumatoid Arthritis Using a Large Observational Database of Japanese Patients Kumi Shidara,Eisuke Inoue,Daisuke Hoshi,Eiichi Tanaka,Yohei Seto,Ayako Nakajima,Shigeki Momohara,Atsuo Taniguchi,Hisashi Yamanaka	2012	14
11	Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA Eiichi Tanaka,Daisuke Hoshi,Ataru Igarashi,Eisuke Inoue,Kumi Shidara,Naoki Sugimoto,Eri Sato,Yohei Seto,Ayako Nakajima,Shigeki Momohara,Atsuo Taniguchi,Kiichiro Tsutani,Hisashi Yamanaka	2012	23
12	Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab Daisuke Hoshi,Ayako Nakajima,Eisuke Inoue,Kumi Shidara,Eri Sato,Mariko Kitahama,Yohei Seto,Eiichi Tanaka,Wako Urano,Naomi Ichikawa,Yumi Koseki,Shigeki Momohara,A Taniguchi,Norihiro Nishimoto,Hisashi Yamanaka	2012	17
13	Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab Daisuke Hoshi,Ayako Nakajima,Eisuke Inoue,Kumi Shidara,Eri Sato,Mariko Kitahama,Yohei Seto,Eiichi Tanaka,Wako Urano,Naomi Ichikawa,Yumi Koseki,Shigeki Momohara,A Taniguchi,Norihiro Nishimoto,Hisashi Yamanaka	2011	33
14	Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study) Tsutomu Takeuchi,Yoshiya Tanaka,Yuko Kaneko,Eiichi Tanaka,Shintaro Hirata,Takahiko Kurasawa,Satoshi Kubo,Kazuyoshi Saito,Kumi Shidara,Noriko Kimura,Hayato Nagasawa,Hideto Kameda,Koichi Amano,Hisashi Yamanaka	2011	31
15	Standard treatment in daily clinical practice for early rheumatoid arthritis improved disease activity from 2001 to 2006 Ayako Nakajima,Eisuke Inoue,Kumi Shidara,Daisuke Hoshi,Eri Sato,Yohei Seto,Eiichi Tanaka,Atsuo Taniguchi,Shigeki Momohara,Hisashi Yamanaka	2011	11
16	Comparison of the second and third generation anti-cyclic citrullinated peptide antibody assays in the diagnosis of Japanese patients with rheumatoid arthritis Kumi Shidara,Eisuke Inoue,Eiichi Tanaka,Daisuke Hoshi,Yohei Seto,Ayako Nakajima,Shigeki Momohara,Atsuo Taniguchi,Hisashi Yamanaka	2010	25
17	Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA Kumi Shidara,Daisuke Hoshi,Eisuke Inoue,Tōru Yamada,Ayako Nakajima,Atsuo Taniguchi,Masako Hara,Shigeki Momohara,Naoyuki Kamatani,Hisashi Yamanaka	2010	48
18	Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA Kumi Shidara,Daisuke Hoshi,Eisuke Inoue,Tōru Yamada,Ayako Nakajima,Atsuo Taniguchi,Masako Hara,Shigeki Momohara,Naoyuki Kamatani,Hisashi Yamanaka	2010	39
19	Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan Kumi Shidara,Eisuke Inoue,Daisuke Hoshi,Eri Sato,Ayako Nakajima,Shigeki Momohara,Atsuo Taniguchi,Hisashi Yamanaka	2010	27
20	Anti‐arthritis effects of vitamin K₂ (menaquinone‐4) − a new potential therapeutic strategy for rheumatoid arthritis Hiroshi Okamoto,Kumi Shidara,Daisuke Hoshi,Naoyuki Kamatani	2007	43

About Kumi Shidara

Kumi Shidara is a scholar working on Rheumatology, Genetics and Hematology, having authored 30 papers that have together received 586 indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (28 papers), Lymphoma Diagnosis and Treatment (9 papers), Chronic Lymphocytic Leukemia Research (8 papers), Autoimmune and Inflammatory Disorders Research (8 papers), Systemic Lupus Erythematosus Research (7 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (5 papers), Biosimilars and Bioanalytical Methods (5 papers) and Hepatitis C virus research (5 papers). The work is most often cited by research in Rheumatology (430 citations), Hematology (126 citations) and Genetics (99 citations). Kumi Shidara has collaborated with scholars based in Japan and Czechia. Frequent co-authors include Hisashi Yamanaka, Shigeki Momohara, Ayako Nakajima, Eisuke Inoue, Atsuo Taniguchi, Daisuke Hoshi, Eiichi Tanaka, Yohei Seto, Eri Sato and Naoki Sugimoto.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact